EA201301295A1 - Композиции антител против cgrp и их применение - Google Patents

Композиции антител против cgrp и их применение

Info

Publication number
EA201301295A1
EA201301295A1 EA201301295A EA201301295A EA201301295A1 EA 201301295 A1 EA201301295 A1 EA 201301295A1 EA 201301295 A EA201301295 A EA 201301295A EA 201301295 A EA201301295 A EA 201301295A EA 201301295 A1 EA201301295 A1 EA 201301295A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cgrp
antibodies
present
binding fragments
application
Prior art date
Application number
EA201301295A
Other languages
English (en)
Other versions
EA031065B1 (ru
Inventor
Браян Роберт Ковасевич
Леон Ф. Гарсия-Мартинес
Кейти Олсон
Бенджамин Х. Дуцар
Дженз Дж. Билгрен
Джон А. Лэтам
Даниэль М. Митчел
Патрисия Дайэн МакНейл
Николь М. Дженсон
Марайа-Кристина Лумис
Original Assignee
Олдербайо Холдингз Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47175055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201301295(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Олдербайо Холдингз Ллк filed Critical Олдербайо Холдингз Ллк
Publication of EA201301295A1 publication Critical patent/EA201301295A1/ru
Publication of EA031065B1 publication Critical patent/EA031065B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Изобретение направлено на антитела и их фрагменты, обладающие специфичностью связывания с CGRP. Еще один вариант воплощения настоящего изобретения относится к антителам, описанным здесь, и их связывающим фрагментам, включая последовательности V, Vи CDR-полипептидов, описанные здесь и полинуклеотиды, кодирующие их. Настоящее изобретение также рассматривает конъюгаты антител против CGRP и их связывающих фрагментов, конъюгированных с одной или более функциональных или обнаруживаемых молекул. Настоящее изобретение также рассматривает способы получения указанных антител против CGRP и их связывающих фрагментов. Варианты воплощения настоящего изобретения также относятся к применению антител против CGRP и их связывающих фрагментов для диагностики, оценки и лечения заболеваний и расстройств, ассоциированных с CGRP.
EA201301295A 2011-05-20 2012-05-21 Композиции антител против cgrp и их применение EA031065B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161488660P 2011-05-20 2011-05-20
PCT/US2012/038844 WO2012162243A2 (en) 2011-05-20 2012-05-21 Anti-cgrp compositions and use thereof

Publications (2)

Publication Number Publication Date
EA201301295A1 true EA201301295A1 (ru) 2014-04-30
EA031065B1 EA031065B1 (ru) 2018-11-30

Family

ID=47175055

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201592042A EA039905B1 (ru) 2011-05-20 2012-05-21 Анти-cgrp антитела и их применение
EA201891284A EA201891284A1 (ru) 2011-05-20 2012-05-21 Композиции антител против cgrp и их применение
EA201301295A EA031065B1 (ru) 2011-05-20 2012-05-21 Композиции антител против cgrp и их применение

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA201592042A EA039905B1 (ru) 2011-05-20 2012-05-21 Анти-cgrp антитела и их применение
EA201891284A EA201891284A1 (ru) 2011-05-20 2012-05-21 Композиции антител против cgrp и их применение

Country Status (35)

Country Link
US (9) US9745373B2 (ru)
EP (5) EP2710039B1 (ru)
JP (3) JP6282584B2 (ru)
KR (1) KR102128627B1 (ru)
CN (5) CN107602700B (ru)
AP (1) AP2013007259A0 (ru)
AR (3) AR086516A1 (ru)
AU (3) AU2012258966C1 (ru)
BR (2) BR112013029932A2 (ru)
CA (3) CA3079978A1 (ru)
CL (3) CL2013003336A1 (ru)
CO (1) CO6870005A2 (ru)
CY (2) CY1124209T1 (ru)
DK (3) DK2710039T3 (ru)
EA (3) EA039905B1 (ru)
ES (3) ES2873837T3 (ru)
FR (1) FR22C1032I2 (ru)
HR (3) HRP20190640T1 (ru)
HU (4) HUE054437T2 (ru)
IL (4) IL229431B (ru)
LT (4) LT3662932T (ru)
MX (3) MX370749B (ru)
NL (1) NL301181I2 (ru)
NZ (1) NZ733060A (ru)
PE (2) PE20180502A1 (ru)
PH (1) PH12018500521A1 (ru)
PL (3) PL3662932T3 (ru)
PT (3) PT3495392T (ru)
RS (3) RS58621B1 (ru)
SG (2) SG194938A1 (ru)
SI (3) SI2710039T1 (ru)
TR (1) TR201904088T4 (ru)
TW (4) TWI646111B (ru)
WO (1) WO2012162243A2 (ru)
ZA (1) ZA201308637B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115333B (en) 2005-11-14 2011-11-25 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin generelated peptide and using same
CN107296957A (zh) 2008-03-04 2017-10-27 梯瓦制药国际有限责任公司 治疗慢性疼痛的方法
WO2012162243A2 (en) * 2011-05-20 2012-11-29 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
WO2012162253A2 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
CN108014334B (zh) * 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
EP3754012A1 (en) 2013-03-15 2020-12-23 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
MX2016000220A (es) * 2013-07-03 2016-08-18 Alder Biopharmaceuticals Inc Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
TWI721976B (zh) 2015-04-16 2021-03-21 美商艾爾德生物製藥股份有限公司 抗ｐａｃａｐ抗體及其用途
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
KR20180058777A (ko) * 2015-09-24 2018-06-01 테바 파마슈티컬스 인터내셔널 게엠베하 (지속성) 외상후 두통의 예방, 치료 및 감소
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2017132062A1 (en) * 2016-01-28 2017-08-03 Eli Lilly And Company Cgrp antibodies and uses thereof
CN108601833B (zh) 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
KR102444717B1 (ko) 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도
SG10201913032TA (en) 2016-09-23 2020-02-27 Teva Pharmaceuticals Int Gmbh Treating refractory migraine
KR20190067181A (ko) 2016-09-23 2019-06-14 테바 파마슈티컬스 인터내셔널 게엠베하 군발성 두통의 치료
WO2018160896A1 (en) * 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
CA3087951A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
JP2021518748A (ja) * 2018-02-23 2021-08-05 アールイーエムディー バイオセラピューティクス，インコーポレイテッドＲＥＭＤ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体
WO2019231800A1 (en) * 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
US10899826B1 (en) * 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
EP3674418A1 (en) * 2018-12-26 2020-07-01 Life Length S.L. Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
SG11202106766SA (en) 2019-01-08 2021-07-29 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies
TW202030205A (zh) * 2019-01-08 2020-08-16 美商Ａｌｄｅｒ製藥公司 使用抗cgrp 或抗cgrp-r 抗體治療藥物過度使用性頭痛
US20220144892A1 (en) * 2019-02-28 2022-05-12 Dandi Bioscience Inc. Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition
BR112020027063A2 (pt) * 2019-05-02 2021-11-16 H Lundbeck As Tratamento de dor de cabeça com uso de anticorpos anti-cgrp
WO2020239014A1 (zh) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 抗cgrp抗体及其应用
BR102020007149A8 (pt) 2020-04-06 2023-09-26 H Lundbeck As Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
WO2022185224A1 (en) 2021-03-02 2022-09-09 Mark Hasleton Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
KR20240049275A (ko) 2021-08-27 2024-04-16 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용한 군발성 두통의 치료
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
CN117586390A (zh) * 2022-08-11 2024-02-23 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3662333A (en) 1970-09-08 1972-05-09 Bendix Corp Hydraulic accumulator charge detector and indicating system
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5123197A (ja) 1974-08-21 1976-02-24 Hitachi Ltd Purosesugasukuromatogurafuno ondoseigyohoshiki
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1985000043A1 (en) * 1983-06-15 1985-01-03 Kingdon Craig R Peptides, pharmaceutical compositions, genes, vectors, host organisms, processes for their production and diagnostic reagents
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
ES2251723T3 (es) 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
JPH11512396A (ja) 1995-09-05 1999-10-26 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
CA2264942A1 (en) 1996-09-09 1998-03-12 Smithkline Beecham Corporation Compounds and methods
ES2314305T3 (es) 1996-09-10 2009-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Aminoacidos modificados, medicamentos que contienen estos compuestos y procedimiento para su obtencion.
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
JP2002525371A (ja) 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
WO2000023579A1 (en) 1998-10-22 2000-04-27 The Regents Of The University Of California Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
MXPA02003108A (es) 1999-09-25 2003-10-14 Univ Iowa Res Found Acidos nucleicos inmunoestimuladores.
EP2341074A1 (en) 2000-03-01 2011-07-06 MedImmune, LLC Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
US20030181462A1 (en) 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
JP2005523418A (ja) 2001-11-26 2005-08-04 プロテミックス コーポレイション リミティド 哺乳動物組織で脂質レベルを正常化するための方法及び組成物
WO2003085089A2 (en) 2002-03-29 2003-10-16 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
AU2003239841A1 (en) 2002-05-06 2003-11-17 Grunenthal Gmbh Cgrp binding nucleic acids
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
HUE032132T2 (en) 2002-06-05 2017-09-28 Bristol Myers Squibb Co Peptide receptor related to calcitonin gene
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
ES2323170T3 (es) 2002-08-12 2009-07-08 Birkir Sveinsson Uso de compuestos antagonistas del cgrp para el tratamiento de la psoriasis.
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CN100434440C (zh) 2002-12-02 2008-11-19 阿布格尼克斯公司 针对肿瘤坏死因子的抗体及其用途
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
ATE509019T1 (de) 2003-03-14 2011-05-15 Merck Sharp & Dohme Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
ATE556060T1 (de) 2003-03-14 2012-05-15 Merck Sharp & Dohme Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
JP4690313B2 (ja) 2003-03-14 2011-06-01 メルク・シャープ・エンド・ドーム・コーポレイション カルボキサミドスピロヒダントインｃｇｒｐ受容体アンタゴニスト
EP1605936B1 (en) 2003-03-14 2011-07-20 Merck Sharp & Dohme Corp. Aryl spirohydantoin cgrp receptor antagonists
WO2004082605A2 (en) 2003-03-14 2004-09-30 Merck & Co. Inc. Bicyclic anilide spirohydantoin cgrp receptor antagonists
CA2522024A1 (en) 2003-04-15 2004-10-28 Merck & Co., Inc. Cgrp receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
CN100418948C (zh) 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
HUE033349T2 (en) 2003-10-22 2017-11-28 Keck Graduate Inst Procedures for the Synthesis of Heteromultimer Polypeptides in Yeast Using an Hagloid Mating Strategy
US20080070239A1 (en) 2003-10-29 2008-03-20 University Of Rochester Detection of neureopeptides associated with pelvic pain disorders and uses thereof
CA2552757A1 (en) 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
WO2007025212A2 (en) 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20070108378A1 (en) 2005-11-14 2007-05-17 Toru Terabayashi High pressure optical cell for a downhole optical fluid analyzer
GEP20115333B (en) * 2005-11-14 2011-11-25 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin generelated peptide and using same
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
US9074352B2 (en) 2006-03-27 2015-07-07 John R. Ramun Universal control scheme for mobile hydraulic equipment and method for achieving the same
US20070269868A1 (en) 2006-05-19 2007-11-22 Carvalho Jensen Anne E Culture method for obtaining a clonal population of antigen-specific B cells
EP2029234A1 (en) 2006-06-08 2009-03-04 Boehringer Ingelheim International GmbH Treatment of gastrointestinal disorders with cgrp-antagonists
ES2343481T3 (es) 2006-07-21 2010-08-02 Vertex Pharmaceuticals, Inc. Antagonistas del receptor cgrp.
US8075902B2 (en) * 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
NZ581418A (en) 2007-05-21 2012-08-31 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
KR101829776B1 (ko) 2007-05-21 2018-02-19 앨더바이오 홀딩스 엘엘씨 Ｉｌ-６에 대한 항체 및 이의 용도
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
GB0725103D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
CN106110321A (zh) * 2008-03-04 2016-11-16 莱布瑞斯生物公司 治疗炎性疼痛的方法
CN107296957A (zh) 2008-03-04 2017-10-27 梯瓦制药国际有限责任公司 治疗慢性疼痛的方法
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
ES2912569T3 (es) 2009-08-28 2022-05-26 Teva Pharmaceuticals Int Gmbh Métodos para tratar el dolor visceral administrando anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US11214610B2 (en) * 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
WO2012162253A2 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
WO2012162243A2 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
KR20180058777A (ko) 2015-09-24 2018-06-01 테바 파마슈티컬스 인터내셔널 게엠베하 (지속성) 외상후 두통의 예방, 치료 및 감소
WO2018160896A1 (en) * 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
US11752099B2 (en) * 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents
WO2018236873A1 (en) * 2017-06-19 2018-12-27 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
TW202030205A (zh) 2019-01-08 2020-08-16 美商Ａｌｄｅｒ製藥公司 使用抗cgrp 或抗cgrp-r 抗體治療藥物過度使用性頭痛
SG11202106766SA (en) 2019-01-08 2021-07-29 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Also Published As

Publication number Publication date
TWI646111B (zh) 2019-01-01
HRP20210777T1 (hr) 2021-06-25
EP3495392A1 (en) 2019-06-12
CA2836649A1 (en) 2012-11-29
AU2019226231A1 (en) 2019-09-26
CN108424452B (zh) 2021-08-03
IL229431A0 (en) 2014-01-30
NZ717570A (en) 2018-09-28
US10533048B2 (en) 2020-01-14
AU2017203890B2 (en) 2019-06-06
CA2836649C (en) 2020-06-23
CL2013003336A1 (es) 2014-06-06
TWI719869B (zh) 2021-02-21
CN107602700B (zh) 2021-12-17
US10189895B2 (en) 2019-01-29
IL229431B (en) 2018-10-31
KR20140042819A (ko) 2014-04-07
HRP20211395T1 (hr) 2021-12-10
FR22C1032I1 (fr) 2022-09-09
US20210047391A1 (en) 2021-02-18
BR112013029932A2 (pt) 2017-01-31
SI2710039T1 (sl) 2019-05-31
EA031065B1 (ru) 2018-11-30
MX370749B (es) 2019-12-20
DK3495392T3 (da) 2021-09-13
CN108373502A (zh) 2018-08-07
US20190211085A1 (en) 2019-07-11
TWI685505B (zh) 2020-02-21
JP2014517699A (ja) 2014-07-24
PT2710039T (pt) 2019-04-23
TW201936642A (zh) 2019-09-16
HUE044062T2 (hu) 2019-09-30
US9745373B2 (en) 2017-08-29
KR102128627B1 (ko) 2020-06-30
TW202033559A (zh) 2020-09-16
US20190092842A1 (en) 2019-03-28
NL301181I1 (ru) 2022-06-15
CL2018001452A1 (es) 2018-08-10
ES2893073T3 (es) 2022-02-07
ES2873837T3 (es) 2021-11-04
SG10201604040PA (en) 2016-07-28
JP6282584B2 (ja) 2018-02-21
CN103748111A (zh) 2014-04-23
CA3080000A1 (en) 2012-11-29
TW201300419A (zh) 2013-01-01
ES2715001T3 (es) 2019-05-31
CN107602700A (zh) 2018-01-19
TR201904088T4 (tr) 2019-05-21
PL2710039T3 (pl) 2019-07-31
JP2019150044A (ja) 2019-09-12
NZ733060A (en) 2022-08-26
US20120294797A1 (en) 2012-11-22
EA201891284A1 (ru) 2018-11-30
EP2710039B1 (en) 2019-01-09
LT2710039T (lt) 2019-04-25
AU2012258966B2 (en) 2017-03-09
US10066009B2 (en) 2018-09-04
CA3079978A1 (en) 2012-11-29
ZA201308637B (en) 2022-11-30
EP3662932B1 (en) 2021-04-07
US10214582B2 (en) 2019-02-26
US20180215813A1 (en) 2018-08-02
CN103748111B (zh) 2018-04-27
US10208112B2 (en) 2019-02-19
AU2019226231B2 (en) 2021-06-03
SG194938A1 (en) 2013-12-30
CO6870005A2 (es) 2014-02-20
FR22C1032I2 (fr) 2023-06-02
NL301181I2 (nl) 2022-11-24
PL3495392T3 (pl) 2021-12-13
US20180215816A1 (en) 2018-08-02
JP6527563B2 (ja) 2019-06-05
HUS2200031I1 (hu) 2022-07-28
WO2012162243A3 (en) 2013-01-17
PH12018500521A1 (en) 2019-04-15
LT3662932T (lt) 2021-06-10
PT3662932T (pt) 2021-05-14
MX2013013535A (es) 2015-08-20
LT3495392T (lt) 2021-09-27
EP3495392B1 (en) 2021-08-18
IL268464A (en) 2019-09-26
CN107586338B (zh) 2021-09-17
EA201592042A1 (ru) 2016-03-31
PT3495392T (pt) 2021-09-22
EA039905B1 (ru) 2022-03-25
PE20180502A1 (es) 2018-03-09
TWI692485B (zh) 2020-05-01
JP6952736B2 (ja) 2021-10-20
NZ618637A (en) 2016-03-31
SI3662932T1 (sl) 2021-08-31
TW201811835A (zh) 2018-04-01
AU2017203890A1 (en) 2017-06-29
AR118605A2 (es) 2021-10-20
IL261927A (en) 2018-10-31
HUE054437T2 (hu) 2021-09-28
CY1124209T1 (el) 2022-05-27
MX2019008185A (es) 2019-09-09
MX2019015745A (es) 2020-02-13
HRP20190640T1 (hr) 2019-05-31
US11111289B2 (en) 2021-09-07
DK2710039T3 (en) 2019-04-01
CN107586338A (zh) 2018-01-16
CL2017001379A1 (es) 2017-12-29
WO2012162243A2 (en) 2012-11-29
SI3495392T1 (sl) 2021-11-30
IL268464B (en) 2020-10-29
EP4115905A1 (en) 2023-01-11
CN108424452A (zh) 2018-08-21
CY1124515T1 (el) 2022-07-22
AP2013007259A0 (en) 2013-11-30
AU2012258966C1 (en) 2022-02-03
EP3662932A1 (en) 2020-06-10
IL261927B (en) 2019-11-28
US20180215814A1 (en) 2018-08-02
DK3662932T3 (da) 2021-05-17
JP2018038391A (ja) 2018-03-15
PE20141787A1 (es) 2014-12-07
US20180215815A1 (en) 2018-08-02
AR086516A1 (es) 2013-12-18
RS58621B1 (sr) 2019-05-31
EP2710039A2 (en) 2014-03-26
US20170174754A1 (en) 2017-06-22
PL3662932T3 (pl) 2021-09-06
EP3875115A1 (en) 2021-09-08
AR123876A2 (es) 2023-01-18
LTPA2022511I1 (ru) 2022-07-11
EP2710039A4 (en) 2014-11-19
RS62306B1 (sr) 2021-09-30
US10179809B2 (en) 2019-01-15
CN108373502B (zh) 2022-03-22
RS61793B1 (sr) 2021-06-30
BR122022012930B1 (pt) 2023-10-10
HUE055505T2 (hu) 2021-11-29
IL270382B (en) 2020-11-30

Similar Documents

Publication Publication Date Title
EA201301295A1 (ru) Композиции антител против cgrp и их применение
TR201905366T4 (tr) IL-6 antikorları ve bunların kullanımı.
NZ702304A (en) Anti-pcsk9 antibodies and use thereof
IN2014MN00873A (ru)
EA201790757A1 (ru) Связывающие антиген cd27l белки
DOP2013000129A (es) PROTEÍNAS DE UNIÓN AL TNF-a.
MX2013006125A (es) Composiciones anti-ngf y uso de las mismas.
EA201170716A1 (ru) Антитела к с-мет
NZ594682A (en) Fully human antibodies specific to cadm1
BR112014015111A2 (pt) composições e processos para anticorpos que se direcionam ao fator p
TR201815254T4 (tr) Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EA201300311A1 (ru) Vegf-связывающие молекулы
EA201591993A1 (ru) Лечение склеродермии с применением комбинированной терапии антителами анти-ccl2 и анти-loxl2
WO2014153117A3 (en) Antibodies to hgf and compositions containing
MX2019006676A (es) Anticuerpos anti-ccl2 para el tratamiento de la esclerodermia.
RU2012113360A (ru) Вариабельные домены легкой и тяжелой цепи мышиного моноклонального антитела против фактора некроза опухоли альфа (фно-альфа) человека (варианты), антигенсвязывающий фрагмент (fab) против фно-альфа человека, содержащий указанные домены (варианты)
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
UA109423C2 (uk) Композиція та спосіб для діагностики і лікування пухлини

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment